- Tumors1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases1000+
- Cancer1000+
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases1000+
- Cancer1000+
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- PD-L1 positive
- HER2 positive
- PR positive
- EGFR positive
- KRAS positive
- ER negative
- EGFR negative
- PD-L1 negative
- PR negative
- BRAF positive
- ALK negative
- CD20 positive
- ALK positive
- p16 positive
- BRCA1 positive
- IDH positive
- BRCA2 positive
- CD19 positive
- PIK3CA positive
- HLA-A positive
- BRAF negative
- HLA positive
- MET positive
- ROS1 positive
- HR positive
- IDH negative
- MYC positive
- RET positive
- ROS1 negative
- HPV positive
- dMMR positive
- BCL2 positive
- MET negative
- MSI-H positive
- NTRK positive
- TP53 positive
- p16 negative
- BCL6 positive
- anti-dsDNA positive
- BRCA positive
- CD5 positive
- FGFR2 positive
- HPV negative
- KRAS negative
- NRAS positive
- PALB2 positive
- PTEN positive
- RAS positive
- TP53 negative
- ANA positive
- FLT3 positive
- HBsAg positive
- HLA negative
- RAS negative
- SMN1 positive
- ctDNA positive
- CCND1 positive
- CFTR positive
- CLDN18.2 positive
- Ex19del positive
- HbSS positive
- L858R positive
- MMR negative
- NF1 positive
- RB1 positive
- RET negative
- BCR-ABL1 positive
- BRCA1 negative
- HLA-A negative
- MSS positive
- NPM1 positive
- NTRK1 positive
- RB1 negative
- dMMR negative
- ABCA4 positive
- BRCA2 negative
- CD20 negative
- CD4 positive
- FLT3 negative
- HBV DNA negative
- KMT2A positive
- MDM2 positive
- MGMT negative
- MMR positive
- MSI-H negative
- NTRK negative
- Philadelphia chromosome negative
- RF positive
- SMN2 positive
- T790M positive
- TTR positive
- pMMR positive
- CD123 positive
- CD19 negative
- CD23 positive
- FGFR3 positive
- FVIII positive
- MLH1 positive
- MSH2 positive
- MSH6 positive
- MSS negative
- NRAS negative
- PMS2 positive
- PTEN negative
- RAF positive
- TROP2 negative
- TROP2 positive
- anti-Sm positive
- 1p negative
- AChR positive
- AKT negative
- AKT positive
- APC positive
- APOL1 positive
- APP positive
- ATM positive
- C5 positive
- CD7 positive
- CLDN6 positive
- COL7A1 positive
- DLL3 positive
- DMD positive
- EBV positive
- FGFR positive
- FMR1 positive
- GPC3 positive
- HBsAg negative
- HRD positive
- HbSC positive
- ICA positive
- KIT positive
- Ki-67 positive
- MGMT positive
- MSI negative
- MTAP positive
- MTOR positive
- MuSK positive
- NY-ESO-1 positive
- PD-1 negative
- PD-1 positive
- PIK3CA negative
- PIK3R1 positive
- PSEN1 positive
- PSEN2 positive
- Philadelphia chromosome positive
- PiZZ positive
- RHO positive
- STK11 positive
- ZnT8 positive
- anti-Ro/SSA positive
- anti-Smith positive
- t(11;14) positive
- β-thalassemia positive
- 11q negative
- 11q positive
- 19q negative
- ABCD1 positive
- AKT1 positive
- ALPL positive
- AXIN1 positive
- Anti-PLA2R positive
- Aβ1-42 positive
- B7-H3 positive
- BRCA negative
- CA-125 positive
- CAG repeat in HTT positive
- CCNE1 positive
- CD1a positive
- CD2 positive
- CD22 negative
- CD22 positive
- CD3 positive
- CD30 positive
- CD33 positive
- CD34 positive
- CD38 positive
- CD4 count positive
- CD8 positive
- CD99 positive
- CDK4 positive
- CEA positive
- CEACAM5 positive
- COL1A1 positive
- COL1A2 positive
- COL3A1 positive
- CTNNB1 positive
- D67N positive
- DGM7 positive
- DMPK positive
- Del(17p) negative
- Del(17p) positive
- EBV DNA positive
- ENPP1 positive
- EPCAM positive
- ER or PR positive
- ER/PR positive
- FGFR1 positive
- FKRP positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Grade 5
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- 30-day washout period after Erythropoietin-Stimulating Agent or IV Iron
- ALK TKI Therapy
- Abrocitinib
- Activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation]
- Active Treatment for Cutaneous Squamous Cell Carcinoma
- Active Treatment for Non-Invasive Basal Cell Carcinoma
- Adjuvant Radiation for 4-6 weeks
- Adjuvant Therapy (except reconstruction)
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
10442 trials
Trials Without a Placebo
Reading, PA (<10 mi)
Waitlist
Phase 2
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug called IW-3300 to see if it can help people with chronic bladder pain. The drug is given as a rectal foam and aims to relieve symptoms like pain, burning, and pressure. Patients will use the drug at home for a few months.
Reading, PA (<10 mi)
Recruiting
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing the addition of radiation therapy to the usual immunotherapy (with or without chemotherapy) treatment for patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (advanced) or has spread to other places in the body (metastatic) and who are also negative for a molecular marker called PD-L1.
Efficacy & Safety Awards
No Placebo-Only Group
Reading, PA (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a 4-drug combo vs. a 3-drug combo to see if the former is more effective in shrinking cancer or preventing its return.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Reading, PA (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a common cancer treatment alone or with a new drug in patients with advanced lung cancer. The chemotherapy kills cancer cells, and the new drug may help the immune system fight the cancer.
Efficacy & Safety Awards
Pivotal Trial
Reading, PA (<10 mi)
Waitlist
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying azacitidine with or without nivolumab or midostaurin, or decitabine and cytarabine alone to see how well they work compared to each other in treating patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Efficacy & Safety Awards
No Placebo-Only Group
Reading, PA (<10 mi)
Waitlist
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing docetaxel in combination with antiandrogen therapy and radiation therapy versus antiandrogen therapy and radiation therapy alone in treating patients with prostate cancer that has been removed by surgery.
Efficacy & Safety Awards
No Placebo-Only Group
Reading, PA (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing nivolumab with or without ipilimumab to see if it can treat patients with squamous cell lung cancer that has come back after previous treatment.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Reading, PA (<10 mi)
Waitlist
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying whether whole-brain radiation therapy is more effective with or without hippocampal avoidance in treating patients with small cell lung cancer.
Efficacy & Safety Awards
No Placebo-Only Group
Reading, PA (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial studies how well nivolumab works in treating patients with non-small cell lung cancer. Nivolumab is an immunotherapy drug that helps the immune system attack cancer cells. The goal is to see if it can prevent the cancer from coming back. Nivolumab has shown efficacy in treating various malignancies, including non-small cell lung cancer.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Get notified when new Non-Small Cell Lung Cancer trials are postedWe'll send you an email whenever new trials are posted
Reading, PA (<10 mi)
Waitlist
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying afatinib dimaleate with or without cetuximab to treat patients with non-small cell lung cancer that has EGFR mutations.
Efficacy & Safety Awards
No Placebo-Only Group
Reading, PA (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares erlotinib hydrochloride to observation in treating patients with resected stage IB-IIIA non-small cell lung cancer. Erlotinib hydrochloride may stop tumor cell growth by blocking enzymes needed for cell growth.
Efficacy & Safety Awards
Pivotal Trial
Reading, PA (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying the combination of exemestane and entinostat to treat patients with hormone receptor-positive breast cancer.
Efficacy & Safety Awards
Pivotal Trial
Reading, PA (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug for breast cancer patients who have a BRCA1/2 mutation and have completed chemotherapy.
Efficacy & Safety Awards
Pivotal Trial
Reading, PA (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying two different combinations of drugs to treat patients with newly diagnosed multiple myeloma.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Reading, PA (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying hormone therapy with or without everolimus to see how well it works in treating patients with breast cancer.
Efficacy & Safety Awards
Pivotal Trial
Reading, PA (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying two different radiation therapy regimens to see how well they work in treating patients with early-stage breast cancer.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Reading, PA (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is comparing radiation therapy with cisplatin to radiation therapy with cetuximab to see which is more effective in treating oropharyngeal cancer.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Reading, PA (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying giving chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Get notified when new Breast cancer trials are postedWe'll send you an email whenever new trials are posted
Reading, PA (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing 4 different hormone therapies with or without chemotherapy to see which is most effective in treating patients with invasive breast cancer.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Reading, PA (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial studies lenalidomide with or without epoetin alfa to treat patients with myelodysplastic syndrome and anemia.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
1
2
3
…50